ArriVent BioPharma, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
ArriVent announced initial Phase 1 data for ARR-217 (CDH17-targeted ADC) from a 123-patient study (113 CRC patients) as of August 5, 2026. At the 6 mg/kg dose, 44.8% ORR (13/29 patients) was observed in heavily pretreated CRC patients with 93.1% disease control rate; safety profile was manageable with 20.4% Grade 3+ adverse events at the 6 mg/kg dose and no Grade 5 events. ARR-217 advances to Phase 1b dose optimization with data expected in 2027.
Why this rating
Early-stage positive clinical data on lead ADC candidate is meaningful for ~$763M biotech; Phase 1 results support advancement but Phase 1b still required; moderate de-risking of pipeline.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.